Shilpa Medicare informs about disclosure

26 Aug 2024 Evaluate
Shilpa Medicare has informed that the company has successfully completed phase 3 clinical studies of its novel product SMLNUD07 - Nor Ursodeoxycholic Acid (NorUDCA) tablets that is expected to revolutionise the treatment of patients suffering from Nonalcoholic Fatty Liver Disease (NAFLD).

The above information is a part of company’s filings submitted to BSE.

Shilpa Medicare Share Price

680.60 3.60 (0.53%)
23-Apr-2025 09:35 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1755.05
Dr. Reddys Lab 1181.30
Cipla 1524.45
Lupin 2067.05
Zydus Lifesciences 857.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...